First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引:1
作者
Ku, G. [1 ]
Shen, L. [2 ]
Klempner, S. J. [3 ]
Pan, H. [4 ]
Kratz, J. [5 ]
Liang, X. [6 ]
Deng, Y. [7 ]
Kim, S. [8 ]
Wang, Z. [9 ]
Feller, L. [10 ]
Powderly, J. [11 ]
Dayyani, F. [12 ]
Schneider, R. E. [13 ]
Girda, E. [14 ]
Berlin, J. D. [15 ]
Spencer, K. [16 ]
Nguyen, M. T. [17 ]
Wang, V. [17 ]
Xu, C. [17 ]
Zhu, A. [18 ]
机构
[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA
[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China
[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA
[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China
[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA
[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China
[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA
[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA
[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA
[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA
[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA
[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA
[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[17] I Mab Biopharma, Res & Dev, San Diego, CA USA
[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China
关键词
D O I
10.1016/j.annonc.2023.09.2178
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1039P
引用
收藏
页码:S631 / S631
页数:1
相关论文
共 50 条
[41]   Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors [J].
Cassier, Philippe A. ;
Borad, Mitesh J. ;
Sharma, Sunil ;
Dubois, Bertrand ;
Caux, Christophe ;
Okano, Fumiyoshi ;
Von Hoff, Daniel D. ;
Blay, Jean-Yves .
CANCER RESEARCH COMMUNICATIONS, 2025, 5 (07) :1119-1128
[42]   First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours [J].
Melero, I. ;
Sanmamed, M. F. ;
Calvo, E. ;
Moreno, I. ;
Moreno, V. ;
Hernandez Guerrero, T. C. ;
Martinez-Garcia, M. ;
Rodriguez-Vida, A. ;
Tabernero, J. ;
Azaro Pedrazzoli, A. B. ;
Spanggaard, I. ;
Rohrberg, K. S. ;
Guarin, E. ;
Nueesch, E. ;
Chesne, E. ;
Ceppi, M. ;
Sweere, U. ;
McIntyre, C. ;
Lichtenegger, F. S. ;
Krieter, O. .
ANNALS OF ONCOLOGY, 2020, 31 :S707-S707
[43]   Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001). [J].
Henry, Jason Timothy ;
Mehnert, Janice M. ;
Rudnicki, Erika ;
Pinelli, Juan ;
Daud, Adil .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44]   A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors [J].
Oh, Do-Youn ;
Lee, Keun-Wook ;
Han, Sae-Won ;
Kim, Jin Won ;
Shin, Jung-Won ;
Jo, Seong-Jin ;
Won, Jonghwa ;
Hahn, Seokyung ;
Lee, Howard ;
Kim, Woo Ho ;
Bang, Yung-Jue .
ONCOLOGIST, 2019, 24 (08) :1037-+
[45]   Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [J].
Bahleda, R. ;
Meric-Bernstam, F. ;
Goyal, L. ;
Tran, B. ;
He, Y. ;
Yamamiya, I ;
Benhadji, K. A. ;
Matos, I ;
Arkenau, H-T .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1405-1412
[46]   A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors [J].
Lassen, U. ;
Schellens, J. H. M. ;
Siu, L. L. ;
Jonker, D. J. ;
Sorensen, M. ;
Jarutat, T. ;
Wang, K. ;
Gehoe, D. ;
DeMario, M. ;
Goss, G. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 :12-12
[47]   A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma [J].
Lin, Tongyu ;
Liu, Bin ;
Pu, Xingxiang ;
Wu, Lin ;
Du, Xiaobo ;
Mo, Ning ;
Song, Zhengbo ;
Zhou, Liwei ;
Duan, Xianlin ;
Zhu, Yanan ;
Kang, Xiaoyan .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48]   First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors [J].
Shitara, Kohei ;
Uehai, Satoshi ;
Shichino, Shigeyuki ;
Aoki, Hiroyasu ;
Ogiwara, Haru ;
Nakatsura, Tetsuya ;
Suzuki, Toshihiro ;
Shimomura, Manami ;
Yoshikawa, Toshiaki ;
Shoda, Kayoko ;
Kitano, Shigehisa ;
Yamashita, Makiko ;
Nakayama, Takayuki ;
Sato, Akihiro ;
Kuroda, Sakiko ;
Wakabayashi, Masashi ;
Nomura, Shogo ;
Yokochi, Shoji ;
Ito, Satoru ;
Matsushima, Kouji ;
Doi, Toshihiko .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 :195
[49]   A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors [J].
Teixeira, Luis ;
Medioni, Jacques ;
Garibal, Julie ;
Adotevi, Olivier ;
Doucet, Ludovic ;
Durey, Marie-Agnes Dragon ;
Ghrieb, Zineb ;
Kiladjian, Jean-Jacques ;
Brizard, Mara ;
Laheurte, Caroline ;
Wehbe, Maria ;
Pliquet, Elodie ;
Escande, Marie ;
Defrance, Remy ;
Culine, Stephane ;
Oudard, Stephane ;
Wain-Hobson, Simon ;
Doppler, Valerie ;
Huet, Thierry ;
Langlade-Demoyen, Pierre .
CLINICAL CANCER RESEARCH, 2020, 26 (03) :588-597
[50]   First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors [J].
Wang, Yakun ;
Gong, Jifang ;
Lin, Rongbo ;
Zhao, Shen ;
Wang, Jufeng ;
Wang, Qianli ;
Zhang, Yanqiao ;
Su, Dan ;
Zhang, Jingdong ;
Dong, Qian ;
Lin, Ling ;
Tian, Wen ;
Chen, Ying ;
Yang, Yang ;
Zhang, Xueyuan ;
Wan, Xuechao ;
Gao, Jinfeng ;
An, Na ;
Jansen, Valerie Malyvanh ;
Shen, Lin .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)